1223593-85-8 Usage
Uses
Used in Pharmaceutical Industry:
(E)-3-(3-(hydrazinecarbonyl)phenyl)-N-hydroxyacrylamide is used as an enzyme inhibitor for its potential to inhibit matrix metalloproteinases (MMPs) and histone deacetylases (HDACs). Its application is aimed at the development of therapeutic agents for the treatment of diseases and conditions where these enzymes play a significant role.
Used in Research and Development:
In the field of scientific research, (E)-3-(3-(hydrazinecarbonyl)phenyl)-N-hydroxyacrylamide serves as a valuable compound for studying the mechanisms of enzyme inhibition and the development of novel drugs targeting MMPs and HDACs. Its unique structure allows researchers to explore its potential in creating new therapeutic strategies for various diseases.
Used in Drug Design and Synthesis:
(E)-3-(3-(hydrazinecarbonyl)phenyl)-N-hydroxyacrylamide is utilized as a key building block in the design and synthesis of new drugs targeting specific enzyme pathways. Its incorporation into drug molecules can potentially enhance the efficacy and selectivity of these therapeutic agents, making it a useful tool in the field of medicinal chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 1223593-85-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,2,3,5,9 and 3 respectively; the second part has 2 digits, 8 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1223593-85:
(9*1)+(8*2)+(7*2)+(6*3)+(5*5)+(4*9)+(3*3)+(2*8)+(1*5)=148
148 % 10 = 8
So 1223593-85-8 is a valid CAS Registry Number.
1223593-85-8Relevant academic research and scientific papers
CLASS- AND ISOFORM-SPECIFIC HDAC INHIBITORS AND USES THEREOF
-
Page/Page column 99-100, (2011/02/24)
HDAC inhibitors of the general formula (I) and (II) and pharmaceutically acceptable salts thereof, as described herein, are useful as inhibitors of histone deacetylases or other deacetylases, and thus are useful for the treatment of various diseases and d
